About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
Feb 28, 2021...
Researchers from the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center have found 30 genes that seem to be responsible for the resistance that multiple myeloma shows to treatment, which may help lead to more informed, personalized treatment for patients.
Malignant myeloma is a cancer of the antibody-producing plasma cells in bone marrow. Most patients develop resistance to medications and in some, the cancer is resistant to therapy from the start.
May 14, 2021... This summer, after more than a year of pandemic shutdowns, we are more excited than ever to get outside. But we can’t let down our guard when it comes to sun exposure, which is the primary cause of the most common cancer in the world: skin cancer. In fact, the Skin Cancer Foundation says that over 85% of melanomas are linked to UV radiation, and having more than five sunburns doubles your risk of developing this deadliest form of skin cancer.
Aug 04, 2022... REHOVOT, ISRAEL—August 4, 2022—The myriads of microbes in our gut, collectively termed the microbiome, are considered important to our health, but they can also harbor bacteria that contribute to inflammatory bowel disease or other disorders. Currently, however, it is impossible to target such disease-contributing bacteria without harming the surrounding beneficial microbes. Antibiotics kill friendly microbes along with the harmful ones, and in any event, they tend to trigger bacterial resistance and to have side effects. In a study published today in Cell, Weizmann Institute of Science researchers have demonstrated the feasibility of a potential therapy for killing inflammation-causing gut bacteria in a targeted manner: by using viruses that infect them.
Sep 08, 2022... REHOVOT, ISRAEL—September 8, 2022—Blood tests – simple, noninvasive and economically feasible – promise to become the next major milestone in cancer diagnosis. However, most of these tests, dubbed liquid biopsies, are currently not reliable enough for widespread use. A new, multiparameter approach developed at the Weizmann Institute of Science may lead to a blood test that will diagnose cancer with unprecedented accuracy. This research is being published today in Nature Biotechnology.
Aug 02, 2023... REHOVOT, ISRAEL—August 2, 2023—Scientific excellence requires diversity – research conducted by people from different backgrounds and with varied worldviews. The need for diversity extends to scientific experiments themselves, but the vast majority of studies in the life sciences are conducted using male mice only, which could not only bias the findings, but impede our ability to extrapolate from them to humans. A new study by researchers from the Weizmann Institute of Science addresses this challenge, revealing in unprecedented detail how the brains of male and female mice respond differently to stress.
Aug 07, 2023...
REHOVOT, ISRAEL — August 8, 2023—Nonsmokers who develop lung cancer can be treated effectively with new drugs, but their tumors refuse to surrender without a fight. The drugs stop working in the long term because the tumors acquire secondary mutations that allow them to evade the medications’ therapeutic effect.
In research published today in the journal Cell Reports Medicine, investigators from the Weizmann Institute of Science report findings that may lead to relapse-free treatment for a sizeable subgroup of lung cancer patients. In a study in mice, scientists identified a biomarker that may help physicians treat select lung cancer patients with a single antibody-based drug that is likely to bring about full remission, without cancer relapse.
©2023 American Committee for the Weizmann Institute of Science
